Reliance Global Group, Inc.

What they do

The Company describes itself as an InsurTech company focused on acquiring, owning and operating wholesale and retail insurance agencies, with primary operations in insurance brokerage. It operates proprietary technology platforms including RELI Exchange and 5MinuteInsure.com. During the first half of 2026 it pursued strategic equity investments in technology and healthcare-related businesses through its Scale 51 operating model and EZRA International Group. It has also expanded into the life sciences sector through LifeSci Global Group LLC and references a digital-asset treasury strategy.

Revenue drivers

• Insurance brokerage operations — The core business is wholesale and retail insurance agency operations, which the 8-K says continued to deliver organic growth in retained operations following divestiture of non-core businesses. Revenue has declined overall, from $14.1M in 2024 to $12.4M in 2025, so this remains the dominant but shrinking revenue base.
• RELI Exchange — A proprietary technology platform named in the 10-Q as part of the Company's primary operations alongside its insurance brokerages. The filings do not break out its standalone revenue contribution.
• 5MinuteInsure.com — A proprietary insurance distribution platform also named as part of primary operations. As with RELI Exchange, no separate revenue figure is disclosed in the excerpts.
• AI platform (browser automation) — A newly launched proprietary AI agent for secure browser automation, being deployed internally across insurance operations and described by management as having long-term commercialization potential. It is not yet reported as a revenue source.

Recent performance

Second quarter 2026 revenue was $2.1M, down from $3.8M in the first quarter of 2026 and $2.6M in the fourth quarter of 2025. The July 30, 2026 earnings release reported that second quarter operating expenses fell about 28% year-over-year and net loss improved about 26% versus the prior-year period. Full-year 2025 revenue was $12.4M with a net loss of $7.0M; the diluted EPS loss was $1.28 for 2025. Operating cash flow was negative $3.1M in 2025 and negative in each year shown since 2021. At June 30, 2026 the Company reported total assets of $12.9M, total liabilities of $6.2M, shareholder equity of $6.7M, cash of $1.8M and long-term debt of $3.8M.

Strategy

Management is positioning Reliance around a proprietary AI platform, launching an AI agent for secure browser automation in July and deploying it across the insurance operations to automate workflows and cut manual processes. The Company says it intends to expand the platform's functionality and commercialize it beyond internal use, targeting regulated industries needing secure workflow automation. Alongside this, Reliance has divested non-core businesses and is pursuing strategic equity investments in technology and healthcare through Scale 51, EZRA International Group and LifeSci Global Group LLC. It also references a digital-asset treasury strategy and blockchain/tokenization initiatives in its forward-looking disclosures. Priorities stated in the second quarter release include growing the InsurTech and insurance operations while investing in AI and managing costs.

Risks

• Need for additional capital — The Company lists its need to raise additional capital, which may not be available on acceptable terms or at all, as a risk, against a backdrop of negative operating cash flow in each year from 2021 through 2025.
• Nasdaq listing compliance — The 10-Q flags maintenance of the $1.00 minimum bid price requirement, the $5.0 million minimum Market Value of Listed Securities requirement, and continued listing on the Nasdaq Capital Market.
• Unproven AI commercialization — The AI platform is newly launched and being deployed internally; the filings state the technology has long-term commercialization potential but disclose no revenue from it, so management's growth thesis depends on execution that is not yet demonstrated.
• Speculative new-sector expansion — The Company cites risks from its expansion into technology and life sciences, including the speculative nature of early-stage investments such as Innervate and conflicts of interest with directors and officers.

Outlook

Management states that its AI platform is being deployed across insurance operations to improve productivity and customer service, and believes the technology has significant long-term commercialization potential beyond internal use. The Company says it intends to expand the platform's functionality across additional business processes and to continue investing in proprietary AI. It states it remains focused on growing its InsurTech and insurance operations while expanding its proprietary technology, with diversification of future revenue opportunities described as a goal.